DEA Schedule II-III registration expands integrated development, testing and clinical supply support for OINDPs CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced that its state-of-the-art formulation, fill and finish services facility in Boonton, New Jersey, has been granted a controlled substances registration authorizing the handling, storage, manufacturing and testing of Schedule II and III contro

Medical Segment Revenue Grows 136% Year-Over-Year Expands CompuFlo® Physician Partnerships and Advances Medical Commercialization Online Demonstrations More Than Double Reflecting Increased Customer Engagement Reaffirms 2026 Outlook for Double-Digit Revenue Growth, Including Significant Growth in CompuFlo® Sales Identifies approximately $400,000 in Additional Annual Savings, Supporting Expectation to Approach or Achieve Profitability in Fourth Quarter 2026 and Additional Profitable Quarters in 2

SEATTLE, WA / ACCESS Newswire / November 12, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced that the Company has entered into warrant inducement letter agreements with certain holders of its existing common warrants (the "Existing Warrants"), pursuant to which such holders have agreed to exercise in full for cash their Existing Warrants to purchase up

Seonix Bio’s SightScore™ Test Uses Saliva to Identify Individuals at High Risk SAN DIEGO--(BUSINESS WIRE)-- Seonix Bio , a leader in the development of genetic testing for glaucoma, today announced new research published in Ophthalmology , the American Academy of Ophthalmology’s peer-reviewed journal. The publication reports that the polygenic risk score (PRS) underlying the company’s SightScore™ test can help identify people at substantially different levels of risk for developing glaucoma—and

Building a National Security Healthcare company focused on dual-use medical technologies Halifax, Nova Scotia--(News - November 12, 2026) - Appili Therapeutics Inc. (NEX: APLI.H) (OTC Pink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company building a National Security Healthcare platform focused on dual-use medical technologies, today announced its financial and operational results for the second quarter of its fiscal year 2027, which ended on September 30, 2026. All figures are in

A major study of nearly 1,900 older adults suggests that stopping statins after age 70 may be relatively safe in the short term for people who have never experienced a heart attack or stroke. However, a higher rate of serious cardiovascular events or death during longer follow-up raises questions about the risks of discontinuing these widely prescribed medications.A major new study suggests that many adults age 70 and older who have never experienced a heart attack or stroke may be able to stop

GOTHENBURG, SE / ACCESS Newswire / November 13, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA) a company discovering and developing novel treatments for Parkinson's disease, today announced that the interim report for the period January-September 2026, has been published. KEY HIGHLIGHTS DURING AND AFTER THE THIRD QUARTER In July, the Company announced that the registered number of shares and votes in IRLAB Therapeutics AB had increased as a result of the rights issue of Class A shares.

• OST-HER2 remains eligible for Priority Review Voucher (“PRV”) if approved by the U.S. Food and Drug Administration’s (“FDA”) on or before September 30, 2029 • Company continues to benefit from its UK research and development program, through which it received approximately $900,000 in non-dilutive tax credits Grasonville, Maryland--(News - November 13, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company") , the world leader in gene-edited, Listeria-based cancer i

WOBURN, Mass., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the quarter ended September 30, 2026. Third Quarter 2026 Highlights Net product revenue of $9.1 million, an increase of 29.8% compared to $7.0 million in the prior-year period. Gross margin of 74.4%, compared to 70.7%

SAN FRANCISCO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce third quarter 2026 financial results on Monday, November 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast Presentation Kyntra Bio management team will host a conference call and webcast presentation to discuss the finan